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DEAR EDITOR, Recent advances in understanding the complex
pathogenesis of atopic dermatitis (AD, also known as eczema
or atopic eczema), coupled with the development of new
treatments, have led to increased interest from multiple stake-
holders. There is a need to prioritize areas for research to
inform a coordinated approach to advancing science and
patient care. We sought to fill a gap in the literature, specifi-
cally from the perspective of clinicians involved in AD patient
care and research.
Our objective was to identify and reach consensus on a set
of research questions to be prioritized for future work in AD.
We conducted a three-round electronic Delphi (eDelphi) pro-
cess with members of the International Eczema Council
(IEC).1,2 The IEC is a global nonprofit organization that aims
to promote the optimal management of AD through research,
education and patient/family care.
In the first round, participants provided online consent and
submitted up to three research questions they believed were
the highest priority in AD. These could include areas of uncer-
tainty (i.e. questions that are not adequately answered by
existing evidence) and/or unmet needs (i.e. areas where there
is not currently ongoing or adequate research). Participants
were asked to align each question to one of the following five
domains: (i) epidemiology, including phenotype, disease
course, disease/psychological burden and comorbidities; (ii)
pathophysiology and molecular mechanisms, including geno-
mics and immunology; (iii) translational research, including
stratified/personalized/precision and systems medicine (in-
cluding models); (iv) therapeutics, including nonpharmaco-
logical interventions such as psychological support and
educational programmes; and (v) other. These domains were
based on a pilot exercise to determine research priorities, car-
ried out with IEC members in 2015, and previous systematic
reviews in dermatology.3 Data were collected using REDCap
software, and free-text responses were reviewed independently
by two researchers.4 Duplicate and overlapping submissions
were aggregated through discussion with the investigator
team.
Round 1 was completed by 68 of 82 invited participants
(83%). Respondents were from 22 countries; 96% were
physicians and 90% were based at teaching hospitals. Among
those caring for patients with AD, 45% cared primarily for
adults, 22% primarily for children and 33% for both. After
consolidation, 62 of 197 priority research questions were put
forward to round 2.
In the second and third rounds, participants were asked to
score each of the submitted questions on a scale from one to
nine using the COMET Initiative Delphi Manager software.5
Consensus was predefined as > 70% of participants scoring
the importance of an item as seven to nine (critically impor-
tant) and < 15% of participants scoring it as one to three (not
important). Questions that did not meet these criteria after
round 2 were dropped, and in round 3, participants were
shown the groups’ scores and asked to re-score each of the
remaining questions.
After the final round, eight research questions achieved con-
sensus and are listed in Table 1. These spanned all domains
and focused on: prediction of disease course; identification of
disease subtypes; evaluation of safe, effective and disease-mod-
ifying therapies; comparative effectiveness of treatments; bio-
marker assessment; and mechanisms and treatment of disease
flares. The consensus that identification of subtypes remains a
priority area for further research is consistent with recent
work in the UK, in which the need to identify subtypes of
patients with differing treatment responses was identified as a
clear priority.6
Our objective was to fill a gap in the literature on research
priorities from the academic clinician/researcher perspective,
given that prior efforts have examined patient, translational
and economic research priorities.6–8 The research questions
identified reveal a different perspective from some patient-led
priority-setting exercises, in which the need for research into
practical issues, such as use of topical steroids and emollients
and food allergy testing, were highlighted.8
Strengths of our work include high response rates and the
clear consensus that emerged. Limitations relate to its general-
izability and the extent to which the priority research ques-
tions reflect all stakeholder priorities for AD research.
Respondents were directly involved in patient care and
reported expertise in various types of AD research but were
predominantly from university teaching hospitals. Geographi-
cally, they worked in six continents with differing socioeco-
nomic contexts, but North America and Europe were
overrepresented. This eDelphi exercise was completed in
February 2020 and thus does not reflect changing priorities as
a result of the global COVID-19 pandemic.
The research questions prioritized indicate the need for
multidisciplinary research including epidemiology, clinical
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trials and molecular medicine to address the outstanding chal-
lenges in understanding this complex disease and optimizing
patient care.
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Table 1 Priority research questions that met consensus criteria










Round 1: submission of questions, 82 IEC members
invited, 68 respondents, 197 questions submitted;
consolidated to 62 priority questions for voting
Round 2: voting, 93 IEC
members invited,b 63
respondents, 8 questions met
criteria
Round 3: repeat voting, 63 IEC
members invited, 59 respondents, 8
questions again met criteria
Can we predict who will develop chronic disease;
associated comorbidities and/or adverse outcomes?
(epidemiology)
3 76 0 83
Can clinically meaningful subtypes of AD be defined based
on age at onset; genetics; environmental factors; and
clinical features? (epidemiology)
5 71 0 82
How do we best classify AD (disease endotype) to predict
clinical outcomes (e.g. prognosis; systemic disease) and
therapeutic outcomes (drug endotype)?
(pathophysiology)
0 73 0 88
Which therapeutic strategies can prevent/modify the
course of AD and prevent the development of
comorbidities? (therapeutics, epidemiology, translational)
0 90 0 88
Which topical and systemic treatments are safest and most
effective for short- and long-term disease control?
(therapeutics)
3 77 2 85
What is the comparative effectiveness and side-effect
profile of systemic AD treatments (both classical and
new)? (therapeutics)
3 72 0 97
How can AD be subclassified using biomarker assessments
and other tests in ways that allow better prediction of
severity; disease course; treatment response; and
comorbidities? (translational, pathophysiology,
therapeutics)
5 78 2 85
What are the mechanisms and potential therapeutic
strategies to reduce and control disease flares in AD?
(translational)
0 70 0 85
AD, atopic dermatitis; IEC, International Eczema Council; aSimilar research questions submitted under more than one domain were combined
after round 1 and listed with multiple domains; bAdditional participants who had become Councillors or Associates of the IEC after the com-
pletion of round 1 were invited to participate in round 2, increasing the total group number.
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